The Food and Drug Administration has approved a new drug that claims to slow the progression of Alzheimer’s disease. The drug is the first approved for Alzheimer’s disease since 2003.

Deficiencies in healthcare systems are emerging in states with some of the fastest growing populations.

Healthcare AI has potential not only for neutralizing its inherent algorithmic bias but also for personalizing its outputs to help humans address health inequities.

Black-box AI should be barred from reading medical images in clinical settings because machine learning, like human thinking, tends to take diagnostic shortcuts. 

When the network interpreted complete videos from 42 consecutive patients, it boosted detection rates by as much as 50% over physician-alone reads.

Upon examining a skin lesion they suspected of being malignant, few dermatologists—only 8%—would hold back from performing a biopsy if an AI tool disagreed, classifying it as benign.

Explainable AI is almost as sharp as human experts when the cause is simple and straightforward, as with ingestion of a single common cleaning product.

JPMorgan Chase is forging a new path in the healthcare space following the downfall of Haven Healthcare, its recent joint venture with Amazon and Berkshire Hathaway.